7 results about "Pulmonary inhalation" patented technology

The present invention provides a process for micronizing and conditioning crystalline indacaterol acetate which yields a micronized product containing low content of amorphous form. The invention also refers to crystalline micronized indacaterol acetate obtained by the process of the invention for use in pharmaceutical compositions for pulmonary inhalation for the treatment of asthma.

The invention provides a preparation method of a lung inhalation microsphere carrying rifapentine, which comprises the following steps: weighing a biodegradable high-molecular polymer and rifapentine, and dissolving the biodegradable high-molecular polymer and the rifapentine in a low-boiling-point organic solvent to form an oil phase; weighing a stabilizer, and dissolving the stabilizer in pure water to form a water phase; slowly dropwise adding the oil phase into the water phase, and stirring and emulsifying at a high speed for 1-30 minutes to form an emulsion; lowering the stirring speed, and continuously stirring for 1-24 hours at a uniform speed until the organic solvent is completely volatilized; carrying out low-speed centrifugation on the residual solution for 1-10 minutes, collecting sustained-release microspheres prepared at the bottom of the solution, then washing the centrifugal microspheres with purified water, and repeating for three times; and freeze-drying a solid product obtained by centrifugation to obtain the microspheres. The production process is simple, the prepared drug-loaded microspheres can accurately deliver drugs to the lung, the drugs can be concentrated at a target site and slowly released after being administered, the maintenance time of the effective concentration of the drugs in local tissues is prolonged, and the compliance of patients is improved.

The present invention relates to an inhalable pharmaceutical composition comprising clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt or a polymorph of clofazimine, or combination thereof, and a pharmaceutically acceptable carrier and / or excipient for use in the treatment or prophylaxis of a nontuberculous bacterial infection of the lungs, wherein clofazimine is in an amount of 1 mg to 20 mg wt % in the composition, and wherein the inhalable pharmaceutical composition is provided by inhalation in an effective daily dose of up to 90 mg of clofazimine. There is also provided pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation for administration alone, or concomitantly with other drugs as combination therapy in the treatment and / or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

The invention discloses a bacillus cereus inhalant and application of the bacillus cereus inhalant in treatment of pulmonary fibrosis. After the pulmonary administration of the bacillus cereus inhalant, more bacillus cereus exist in the lung, the bacillus cereus secretes collagenase, and the collagenase degrades collagen in fibrotic tissues, so that the pulmonary fibrosis resisting effect is achieved. After pulmonary fibrosis model animals inhale the bacillus cereus inhalant, the respiratory function and the athletic ability are greatly improved, the respiratory function and the athletic ability are remarkably different from those of non-administrated model animals in the aspects of lung tissue appearance, collagen deposition, the inflammatory factor level and the hydroxyproline level, and part of indexes are close to those of healthy animals.

The invention belongs to the technical field of biological medicines, and particularly relates to acacetin-containing lipid nanoparticles for a pulmonary inhalation type mRNA vaccine as well as a preparation method and application of the acacetin-containing lipid nanoparticles. The lipid nano-particle takes acacetin as a functional fifth component, is jointly composed of ionized lipid, neutral auxiliary lipid, cholesterol and polyethylene glycol lipid, and can effectively wrap mRNA (messenger Ribonucleic Acid) of an encoding antigen. According to the preparation method, high-efficiency compounding of lipid and mRNA is realized through a microfluidic technology, the particle size of the obtained particles is adaptive to lung targeting, alveolar macrophage removal can be reduced, mRNA is protected from peroxidation damage, and vaccine response is enhanced through the immunomodulatory effect of acacetin. The system can be prepared into a lung inhalation type mRNA vaccine, is used for preventing and controlling respiratory tract infectious diseases, has high-efficiency delivery, strong immunization and good safety, and provides a new scheme for construction of a lung immune barrier.

The application discloses a kind of liposome polypeptide vaccine of pulmonary inhalation immunity and its preparation method and application, belong to biological medicine technical field.The vaccine includes the liposome of DSPC and DDAB, polypeptide antigen and molecular adjuvant loaded therein.The optimal preparation process condition is: the mass ratio of DSPC and DDAB 5:1, ultrasonic power 275 W, ultrasonic number 50 times, the liposome particle size obtained is about 100 nm, surface is positive charge, meet the physical property requirement of respiratory mucosa immunity.The vaccine can be widely distributed in lung and long time retention after pulmonary mucosa route immunity, promote the uptake and activation of dendritic cell in lung to antigen, further activate T, B cell, produce mucosal immune response, and be taken up after dendritic cell, transport to lymph node, stimulate systemic adaptive immune response.The application provides effective mucosal immune vaccine platform for the prevention and treatment of respiratory pathogenic microorganism infection.

A process for manufacturing a Treprostinil-diketopiperazine dry powder for pharmaceutical use by spray drying a suspension without need to dissolve Treprostinil in an alcohol solution prior to processing. In some embodiments, the dry powder is for oral inhalation for pulmonary delivery using a dry powder inhaler.